Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 51

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 51
---
 price of our securities.

Our operating results will be affected by numerous factors such as:

 ·variations in the level of expenses related to our proposed products;    ·status of our product development efforts;    ·execution of collaborative, licensing or other arrangements, and the timing of payments received or made under those arrangements;    ·intellectual property prosecution and any infringement lawsuits to which we may become a party;

 37Table of Contents

 ·regulatory developments affecting our products or those of our competitors, including the timing and success of obtaining various regulatory approvals for our products’ testing, production and marketing;    ·our ability to obtain and maintain FDA clearance and approval from foreign regulatory authorities for our products, which have not yet been approved for marketing;    ·market acceptance of our TAEUS applications;    ·the availability of reimbursement for our TAEUS applications;    ·our ability to attract new customers and grow our business with existing customers;    ·the timing and success of new product and feature introductions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners;    ·the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations;    ·changes in our pricing policies or those of our competitors;    ·general economic, industry and market conditions;    ·the hiring, training and retention of key employees, including our ability to expand our sales team;    ·litigation or other claims against us;    ·our ability to obtain additional financing; and    ·advances and trends in new technologies and industry standards.

Any or all of these factors could adversely affect our cash position requiring us to raise additional capital which may be on unfavorable terms and result in substantial dilution. Additionally, the risks surrounding our business, as well as the limited market for our common stock, have resulted, and will likely continue to result, in volatility in the price of our common stock. 

Our stock is subject to minimum requirements to remain listed on the Nasdaq Capital Market, including a minimum bid price requirement and stockholders’ equity requirement, and may be delisted if it does not maintain compliance with those requirements.

On May 3, 2024, the Company received a notification letter from the Listing Qualifications Department of Nasdaq notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for